tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

CTVA · Q2 2025 Earnings

Corteva

Reported August 6, 2025

30-second summary

Corteva delivered $6.46B revenue (+5.6% YoY) and non-GAAP EPS of $2.20 in Q2, with both segments growing — Seed +4.8% and Crop Protection +7.7% on five consecutive quarters of volume growth. Management raised every line of FY2025 guidance: operating EPS to $3.00–$3.20 (+21% YoY at midpoint), operating EBITDA to $3.75–$3.85B (+13%), free cash flow to ~$1.9B, and the net cost improvement target to $450M from $400M after exceeding the original target in H1 alone. The tone is unusually forward-leaning for an ag-inputs name facing commodity headwinds — the net royalty neutrality target was pulled forward from 2030 to 2028, and out-licensing was reframed from emerging opportunity to a $4B core strategic pivot.

Headline numbers

EPS

Q2 FY2025

$2.20

Revenue

Q2 FY2025

$6.46B

+5.6% YoY

Gross margin

Q2 FY2025

54.6%

Operating margin

Q2 FY2025

27.9%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$6.46B+5.6%
EPS$2.20—
Gross margin54.6%—
Operating margin27.9%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Seed$4.537B+4.8%
Crop Protection$1.919B+7.7%
Seed - Corn revenue$2,961M—
Seed - Soybean revenue$1,257M—
Crop Protection - Herbicides revenue$995M—
Crop Protection - Fungicides revenue$342M—

Other KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Seed - North America$3.954B+5.4%
Seed - EMEA$0.282B+12.4%
Seed - Latin America$0.154B-25.6%
Seed - Asia Pacific$0.147B+22.5%
Crop Protection - North America$0.675B+4.3%
Crop Protection - Latin America$0.518B+16.9%
Operating EBITDA$2,164M—
Operating EBITDA margin33.5%—
Organic sales growth6.5%—
Base income tax rate22.3%—

Management tone

Management is more confident and forward-leaning than typical for a company facing commodity-price headwinds. Three shifts stand out.

Cost program pulled forward from a defensive lever to an accelerant. What was a $400M FY2025 net cost improvement target at the start of the year has now been exceeded in H1 alone, with the full-year bar raised to $450M. Chuck framed it as: "We exceeded our 2025 net cost improvement target in the first half alone, allowing us to raise our full year target to 450 million from 400 million." This matters because the 2027 framework hinges on a $700M cumulative cost target — beating H1 by this margin de-risks the credibility of the longer-dated number.

Seed business model reframed from in-licensing to out-licensing. Management characterized this as a "really interesting strategic pivot," sizing the global out-licensing opportunity in corn and soybeans at $4B and noting some of it has already been pulled forward. Connected to this, the net royalty neutrality target moved from end-of-decade (2030) to 2028. The signal: management believes the seed IP portfolio is strong enough to sell rather than lease — Chuck noted the business is on a pivot where "we're not in licensing technology as much as we're outlicensing technology."

Crop Protection pricing narrative shifted from "stabilizing" to "stabilized, with early improvement signs." China generic pricing has been flat for four consecutive quarters per Chuck — "for four quarters now in a row, the pricing is stable. So it's no longer going down for almost a year, which I think is great." The five-quarter volume growth streak in CP, combined with stabilizing generic pricing, suggests the worst of the destocking cycle is behind. Management still flagged low-to-mid single-digit CP price declines in H2 Brazil as the residual risk.

H2 framing tilted positive. What had been "modest growth in the second half" is now "mid single-digit growth" as a de-risked baseline. David Johnson explicitly tied the guidance raise to "record first half performance and de-risk expectations of modest growth in the second half."

Recurring themes management leaned on this quarter:

Operational excellence and productivity acceleration ahead of scheduleStrong North America seed market share gains in both corn and soybeansCrop protection volume growth (5 consecutive quarters) offsetting pricing pressureStrategic shift from in-licensing to out-licensing of seed technologyNew product platforms (VORSEED, Power Core, fungicides) driving differentiationMarket fundamentals stronger than commodity pricing suggests

Risks management surfaced:

Crop protection pricing headwinds in Brazil (low to mid single digit declines expected H2)Currency headwinds, particularly Brazilian real and Turkish lira (~$150M H1 impact)Geopolitical uncertainty and trade route openness affecting soybean demandWorking capital dependent on crop prepaid deposits in Q4Potential return of Dicamba label and competitive implications

What to watch into next quarter

Seed Latin America recovery in Q3/Q4. The −25.6% Q2 print is the only negative growth line in the deck; watch whether the LatAm planting-season ramp restores positive YoY by Q4, particularly given Brazilian real and soybean trade-route uncertainty.

Crop Protection pricing in Brazil during H2. Management guided to low-to-mid single-digit CP price declines in H2; watch whether CP volume growth (now five quarters running) can continue to more than offset, keeping segment revenue growth positive.

Cost program execution beyond $450M. Having beaten the original $400M target in H1 alone, watch whether the raised $450M FY bar proves conservative again — material upside here is the most credible path to the 2027 framework's $700M cumulative cost number.

Out-licensing revenue disclosure. Management sized the opportunity at $4B and said some has been "pulled forward"; watch whether Q3 brings explicit out-licensing revenue or deal-count disclosure to convert narrative into quantifiable run-rate.

Q4 working capital and FCF conversion. The ~$1.9B FCF guide implies ~50% conversion and is heavily back-loaded; watch whether crop prepaid deposits land as planned, since the FCF print is the cleanest test of the raised guide.

Sources

  1. Corteva Q2 2025 Earnings Schedules, SEC Form 8-K (June 30, 2025 period): https://www.sec.gov/Archives/edgar/data/1755672/000175567225000015/a63025enrschedules.htm
  2. Corteva Q2 2025 earnings call commentary (Chuck Magro, David Johnson) — guidance, cost-program, and out-licensing remarks as cited above.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.